Literature DB >> 18391986

Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes.

A Bheda1, K E Creek, L Pirisi.   

Abstract

Overexpression of the epidermal growth factor receptor (EGFR) in human papillomavirus type 16-immortalized human keratinocytes (HKc) is caused by the viral oncoprotein E6, which targets p53 for degradation. We have previously observed that expression of p53 RNAi in normal HKc is associated with an increase in EGFR mRNA and protein. We now report that p53 RNAi induces EGFR promoter activity up to approximately 10-fold in normal HKc, and this effect does not require intact p53 binding sites on the EGFR promoter. Exogenous wild-type p53 inhibits the EGFR promoter at low levels, and activates it at higher concentrations. Yin Yang 1 (YY1), which negatively regulates p53, induces EGFR promoter activity, and this effect is augmented by p53 RNAi. Intact p53 binding sites on the EGFR promoter are not required for activation by YY1. In addition, Sp1 and YY1 synergistically induce the EGFR promoter in normal HKc, indicating that Sp1 may recruit YY1 as a co-activator. Wild-type p53 suppressed Sp1- and YY1-mediated induction of the EGFR promoter. We conclude that acute loss of p53 in normal HKc induces EGFR expression by a mechanism that involves YY1 and Sp1 and does not require p53 binding to the EGFR promoter.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18391986      PMCID: PMC2572188          DOI: 10.1038/onc.2008.65

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  32 in total

1.  Identification and classification of p53-regulated genes.

Authors:  J Yu; L Zhang; P M Hwang; C Rago; K W Kinzler; B Vogelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

2.  Analysis of p53-regulated gene expression patterns using oligonucleotide arrays.

Authors:  R Zhao; K Gish; M Murphy; Y Yin; D Notterman; W H Hoffman; E Tom; D H Mack; A J Levine
Journal:  Genes Dev       Date:  2000-04-15       Impact factor: 11.361

3.  Human papillomavirus type 16 E6 and E7 cooperate to increase epidermal growth factor receptor (EGFR) mRNA levels, overcoming mechanisms by which excessive EGFR signaling shortens the life span of normal human keratinocytes.

Authors:  G S Akerman; W H Tolleson; K L Brown; L L Zyzak; E Mourateva; T S Engin; A Basaraba; A L Coker; K E Creek; L Pirisi
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

4.  p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription.

Authors:  Steven A Innocente; Jonathan M Lee
Journal:  FEBS Lett       Date:  2005-01-13       Impact factor: 4.124

5.  Activator protein-1 mediates induced but not basal epidermal growth factor receptor gene expression.

Authors:  A C Johnson; B A Murphy; C M Matelis; Y Rubinstein; E C Piebenga; L M Akers; G Neta; C Vinson; M Birrer
Journal:  Mol Med       Date:  2000-01       Impact factor: 6.354

6.  Transcriptional regulation of ATP2C1 gene by Sp1 and YY1 and reduced function of its promoter in Hailey-Hailey disease keratinocytes.

Authors:  Hiroshi Kawada; Chiharu Nishiyama; Atsushi Takagi; Tomoko Tokura; Nobuhiro Nakano; Keiko Maeda; Nobuyasu Mayuzumi; Shigaku Ikeda; Ko Okumura; Hideoki Ogawa
Journal:  J Invest Dermatol       Date:  2005-06       Impact factor: 8.551

Review 7.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

8.  Yin yang 1 negatively regulates the differentiation-specific E1 promoter of human papillomavirus type 6.

Authors:  W Ai; J Narahari; A Roman
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

9.  Regulation of transcription factor YY1 by acetylation and deacetylation.

Authors:  Y L Yao; W M Yang; E Seto
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

Review 10.  Transcription factor YY1: structure, function, and therapeutic implications in cancer biology.

Authors:  S Gordon; G Akopyan; H Garban; B Bonavida
Journal:  Oncogene       Date:  2006-02-23       Impact factor: 9.867

View more
  22 in total

1.  Cancer/testis antigen CAGE exerts negative regulation on p53 expression through HDAC2 and confers resistance to anti-cancer drugs.

Authors:  Youngmi Kim; Hyunmi Park; Deokbum Park; Yun-Sil Lee; Jongseon Choe; Jang-Hee Hahn; Hansoo Lee; Young-Myeong Kim; Dooil Jeoung
Journal:  J Biol Chem       Date:  2010-06-08       Impact factor: 5.157

Review 2.  The oncogenic role of Yin Yang 1.

Authors:  Qiang Zhang; Daniel B Stovall; Kazushi Inoue; Guangchao Sui
Journal:  Crit Rev Oncog       Date:  2011

3.  Stem Cell Properties of Normal Human Keratinocytes Determine Transformation Responses to Human Papillomavirus 16 DNA.

Authors:  Yvon Woappi; Maria Hosseinipour; Kim E Creek; Lucia Pirisi
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

4.  PU.1-dependent regulation of UCH L1 expression in B-lymphoma cells.

Authors:  Anjali Bheda; Wei Yue; Anuradha Gullapalli; Julia Shackelford; Joseph S Pagano
Journal:  Leuk Lymphoma       Date:  2011-04-20

5.  Long-term treatment with EGFR inhibitor erlotinib attenuates renal inflammatory cytokines but not nephropathy in Alport syndrome mouse model.

Authors:  Kohei Omachi; Rui Miyakita; Ryosuke Fukuda; Yukari Kai; Mary Ann Suico; Tsubasa Yokota; Misato Kamura; Tsuyoshi Shuto; Hirofumi Kai
Journal:  Clin Exp Nephrol       Date:  2017-02-08       Impact factor: 2.801

6.  VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.

Authors:  Cheng Liu; Li Liu; Kun Wang; Xiao-Feng Li; Li-Yuan Ge; Run-Zhuo Ma; Yi-Dong Fan; Lu-Chao Li; Zheng-Fang Liu; Min Qiu; Yi-Chang Hao; Zhen-Feng Shi; Chuan-You Xia; Klas Strååt; Yi Huang; Lu-Lin Ma; Dawei Xu
Journal:  Oncogene       Date:  2020-04-14       Impact factor: 9.867

7.  TGF-β regulation of gene expression at early and late stages of HPV16-mediated transformation of human keratinocytes.

Authors:  Sangeeta Kowli; Rupa Velidandla; Kim E Creek; Lucia Pirisi
Journal:  Virology       Date:  2013-09-19       Impact factor: 3.616

Review 8.  Targeted therapies: the rare cancer paradigm.

Authors:  Marco A Pierotti; Tiziana Negri; Elena Tamborini; Federica Perrone; Sabrina Pricl; Silvana Pilotti
Journal:  Mol Oncol       Date:  2009-10-28       Impact factor: 6.603

9.  miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.

Authors:  D Yin; S Ogawa; N Kawamata; A Leiter; M Ham; D Li; N B Doan; J W Said; K L Black; H Phillip Koeffler
Journal:  Oncogene       Date:  2012-05-14       Impact factor: 9.867

10.  TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy.

Authors:  A Oden-Gangloff; F Di Fiore; F Bibeau; A Lamy; G Bougeard; F Charbonnier; F Blanchard; D Tougeron; M Ychou; F Boissière; F Le Pessot; J-C Sabourin; J-J Tuech; P Michel; T Frebourg
Journal:  Br J Cancer       Date:  2009-04-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.